Shares of other companies:
April 26, 2024 Top 10 High Dividend Yield Stocks
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
GTHX Stock News and Mentions of G1 Therapeutics, Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where G1 Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of G1 Therapeutics, Inc. (GTHX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the G1 Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of G1 Therapeutics, Inc. (GTHX)
April 17, 2024 (13:00) / "GlobeNewswire" (by G1 Therapeutics)
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May ...
In Article Trend: Neutral
April 4, 2024 (14:30) / "Business Insider" (by markets.businessinsider.com)
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 ( GLOBE NEWSWIRE ) -- G1 Therapeutics, Inc. ( Nasdaq: GTHX ) , a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare ...
In Article Trend: Neutral
April 4, 2024 (14:30) / "GlobeNewswire" (by G1 Therapeutics)
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 ( GLOBE NEWSWIRE ) -- G1 Therapeutics, Inc. ( Nasdaq: GTHX ) , a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare ...
In Article Trend: Neutral
April 1, 2024 (20:20) / "Benzinga" (by Globe Newswire)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - G1 Therapeutics ( NASDAQ:GTHX )
RESEARCH TRIANGLE PARK, N.C., April 01, 2024 ( GLOBE NEWSWIRE ) -- G1 Therapeutics, Inc.
In Article Trend: Somewhat-Bullish
April 1, 2024 (20:20) / "GlobeNewswire" (by G1 Therapeutics)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:20) / "Benzinga" (by Globe Newswire)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - G1 Therapeutics ( NASDAQ:GTHX )
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 ( GLOBE NEWSWIRE ) -- G1 Therapeutics, Inc.
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:20) / "GlobeNewswire" (by G1 Therapeutics)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (19:18) / "Investor Ideas"
Oncology Stock News Bite - G1 Therapeutics ( NASDAQ: GTHX ) Trades Up on Fourth Quarter and Full Year 2023 Financial Results
Oncology Stock News Bite - G1 Therapeutics ( NASDAQ: GTHX ) Trades Up on Fourth Quarter and Full Year 2023 ... ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (12:40) / "Zacks Commentary" (by Zacks Equity Research)
G1 Therapeutics ( GTHX ) Reports Q4 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 22.22% and 15.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 28, 2024 (11:30) / "GlobeNewswire" (by G1 Therapeutics)
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Achieved $46.3 Million in Net Revenue from Sales of COSELA® ( trilaciclib ) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA Revenue Grew 29% in the Fourth Quarter of 2023 to $13.9 Million -
In Article Trend: Neutral
February 27, 2024 (13:30) / "Benzinga" (by Globe Newswire)
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference - G1 Therapeutics ( NASDAQ:GTHX )
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- G1 Therapeutics, Inc. GTHX, a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual ...
In Article Trend: Neutral
February 27, 2024 (13:30) / "GlobeNewswire" (by G1 Therapeutics)
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- G1 Therapeutics, Inc. ( Nasdaq: GTHX ) , a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website